JOHNSON & JOHNSON

Pharmaceutical Preparations·NEW BRUNSWICK, NJ·FY end 01/03·CIK 200406

Named Executive Officers

FY 2025

Executive	Salary	Stock	Options	Bonus / Inc.	Other	Total
J. DuatoChairman/CEO	$1.6M	$15.0M	$5.9M	$4.3M	$5.9M	$32.8M
J. ReedEVP, Innovative Medicine, R&D	$1.2M	$2.4M	$1.8M	$6.6M	$12.3M	—
J. TaubertEVP, WWC Innovative Medicine	$1.2M	$2.4M	$2.0M	$8.3M	$14.1M	—
J. WolkEVP, CFO	$1.2M	$2.5M	$1.9M	$8.7M	$14.5M	—
T. SchmidEVP, WWC, MedTech	$942.3K	$1.3M	$1.5M	$5.4M	$9.4M	—

J. Duato · FY 2025

Stock awards$15.0M46%

Performance bonus$4.3M13%

Salary$1.6M5%

Other$11.8M36%

TSR % vs. CEO comp actually paid · 5 fiscal years · Item 402(v) disclosure

TSR

CEO comp

FY21

+11%

$39M

FY22

+18%

$19M

FY23

+8%

$14M

FY24

+3%

$17M

FY25

+52%

$68M

Need at least two fiscal years of proxy data to draw the trend line. The ingestion worker will populate prior-year proxies as it processes them.